gilead forecast 2021 growth, strong remdesivir covid-19 sale
(reuter) - gilead scienc inc on thursdai forecast it 2021 result abov wall street estim after post a 26% rise in fourth-quarter 2020 revenu, driven by sale of it antivir drug, remdesivir, which is us to treat covid-19 patient.
